The validation of new CHD1L inhibitors as a therapeutic strategy for cancer
2023 · Biomedicine & Pharmacotherapy · 8 citations
https://doi.org/10.1016/j.biopha.2023.116037
H
Hector Esquer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
31
Papers
470
Citations
9
h-index
9
i10-index
Hector Esquer is an academic researcher from University of Colorado Cancer Center. The author has contributed to research in topics: PARP inhibition in cancer therapy & Cancer, Hypoxia, and Metabolism & Ubiquitin and proteasome pathways. The author has an h-index of 9, co-authored 27 publications.
ORCID: 0000-0002-1911-1523Papers by this author
worksHTS discovery of PARP1-HPF1 complex inhibitors in cancer
2023 · SLAS DISCOVERY · 7 citations
https://doi.org/10.1016/j.slasd.2023.10.003
Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer
2025 · Cells · 5 citations
https://doi.org/10.3390/cells14050318
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat